Logo

Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease

Share this

Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease

Shots:

  • Prometheus to receive up front- $420M as development- regulatory & commercial milestone with royalties on sales of each program and will be responsible for the identification and validation of three unique drug targets. Takeda to discover- develop & commercialize up to three targeted IBD therapeutics and companion diagnostics
  • The collaboration combines Prometheus' bioinformatics analysis platform and CDx with Takeda’s expertise in gastroenterology and drug development to speed up the development and discovery of targeted IBD therapies And CDx
  • The targeted precision medicines are needed to deliver new- effective therapeutic options in inflammatory bowel disease

Click here to­ read full press release/ article

 Ref: PRNewswire | Image: Takeda


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions